- Home
- TALO vs TSHA Comparison
TALO vs TSHA Comparison
Compare TALO & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | TSHA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TALO | TSHA |
|---|---|---|
| Price | $11.33 | $4.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $13.38 | $10.56 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,780,070,000.00 | $8,333,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.23 | $1.13 |
| 52 Week High | $13.85 | $6.02 |
Technical Indicators
Market Signals| Indicator | TALO | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 52.84 |
| Support Level | $10.37 | $4.41 |
| Resistance Level | $12.11 | $5.39 |
| Average True Range (ATR) | 0.58 | 0.24 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 4.75 | 66.67 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.